Hemostatic medicines are drugs and materials designed to stop bleeding, and they range from gauze impregnated with clotting activators to intravenous drugs that shore up the body’s own coagulation machinery. In emergency rooms, operating theaters, and battlefield first-aid kits, these agents fill a critical gap when the body’s natural clotting response is too slow, overwhelmed, or pharmacologically impaired. The field has expanded dramatically over the past two decades, and choosing the right hemostat now depends on whether bleeding is on the surface or deep inside the body, whether the patient’s clotting system is intact or compromised, and how quickly help can arrive.
How the Body Normally Stops Bleeding
Understanding hemostatic medicines starts with a quick look at what they’re trying to assist or replace. When a blood vessel tears, the body launches a chain reaction. Tissue factor at the injury site kicks off the coagulation cascade, generating small amounts of thrombin. That initial thrombin activates platelets and several clotting factors, which amplify the process and produce much larger quantities of thrombin. Thrombin then converts fibrinogen into fibrin strands that weave together into an insoluble mesh, physically plugging the wound.1PubMed Central. Back to basics: the coagulation pathway Every hemostatic medicine works by intervening at one or more points in this sequence, whether by providing a physical scaffold for clot formation, supplying missing clotting factors, or preventing existing clots from dissolving too quickly.
Topical Hemostats Applied Directly to Wounds
Topical hemostats are the most visible category. They are applied directly to a bleeding surface during surgery or in the field, and they work through different mechanisms depending on their composition.
Oxidized regenerated cellulose, one of the oldest and most widely used surgical hemostats, swells on contact with blood and forms a gel-like mass that provides both a physical barrier and a mildly acidic environment that promotes clotting. Newer formulations of oxidized cellulose have shown faster times to hemostasis compared with older versions in animal models of liver bleeding.2PubMed Central. A systematic review on the use of topical hemostats in trauma and emergency surgery Gelatin-based sponges work similarly by absorbing blood and concentrating platelets at the wound surface. Collagen-based products attract platelets directly, encouraging the first steps of clot formation.
Chitosan-based hemostats deserve their own mention because they work through a fundamentally different mechanism. Chitosan is a positively charged polymer derived from crustacean shells, and it attracts negatively charged red blood cells to clump together, promoting coagulation independently of the classical coagulation cascade.3PubMed Central. Application and outlook of topical hemostatic materials: a narrative review – Section: Chitosan This independence from the body’s own clotting factors is a major advantage in patients who are hypothermic, acidotic, or on blood thinners, situations where the coagulation cascade is sluggish or broken.
Fibrin sealants represent the most biologically active topical option. These two-component products combine fibrinogen with thrombin, essentially delivering the final step of the coagulation cascade directly to the wound. When the two components meet at the tissue surface, they form a fibrin clot within seconds. The concept dates back over a century: topical fibrin for hemostasis was first discussed in 1909, and purified thrombin became commercially available by 1938. Clinical use accelerated through the 1940s and has broadened ever since.
Hemostats on the Battlefield and in Prehospital Care
Military medicine has been one of the most aggressive proving grounds for hemostatic products, because uncontrolled hemorrhage is the leading cause of preventable death on the battlefield. Combat Gauze, impregnated with kaolin (a mineral that activates the contact pathway of clotting), became the standard issue for U.S. military medics. But chitosan-based products like Celox Gauze and ChitoGauze have demonstrated equal performance across multiple studies, with the added benefit of working independently of the body’s own clotting machinery.4Military Medicine. Review of New Topical Hemostatic Dressings for Combat Casualty Care That matters in combat because injured soldiers are often hypothermic and in shock, conditions that impair normal clotting.
A review of prehospital hemostatic use in Iraq and Afghanistan documented 258 patients who received hemostatic agents, split between chitosan-based and kaolin-based products.5PubMed. Prehospital Application of Hemostatic Agents in Iraq and Afghanistan That number may seem small relative to total casualties, reflecting the reality that these products are reserved for wounds where direct pressure alone fails. The lessons learned from military use have since filtered into civilian emergency medicine. Many civilian ambulance services now carry hemostatic gauze for junctional wounds in the groin, axilla, or neck where tourniquets cannot be applied.
One practical concern for field use is whether these products survive extreme environmental conditions. A recent study tested hemostatic gauze after prolonged exposure to temperature extremes and found that the gauze retained its ability to initiate clotting even after harsh conditions, with consistent reductions in the time to clot initiation across all temperatures tested.6PubMed. Impact of Extreme Temperatures on Hemostatic Gauze Using Thromboelastography Not all hemostatic products are so resilient. Reconstituted fibrinogen concentrate, for example, maintained its clotting function when frozen for six months but began to degrade after about a week at room temperature and lost all hemostatic function after just eight hours at 50°C.7PubMed. Stability of Reconstituted Fibrinogen Concentrate in Hemostatic Function and Concentration For military planners and remote emergency services, those storage constraints directly affect which products can be stocked in vehicles and backpacks versus those that require refrigeration.
Systemic Hemostatic Medicines Given Intravenously
When bleeding is internal, surgically inaccessible, or too diffuse for a topical approach, systemic hemostatic drugs enter the picture. The most widely used is tranexamic acid, an antifibrinolytic drug that prevents the breakdown of fibrin clots. It does not help form new clots; instead, it keeps existing ones intact by blocking the enzyme plasmin from chewing through fibrin meshwork. This makes it useful whenever the body is dissolving clots faster than it can build them.
In severely injured patients arriving at the hospital, the balance between clot formation and clot breakdown is often disturbed. Roughly one in five severely injured patients arrives with hyperfibrinolysis, meaning their clots are dissolving too quickly, while a much larger proportion shows the opposite pattern, called fibrinolysis shutdown, where the clot-dissolving system has been suppressed.8PubMed Central. Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient That distinction matters because giving an antifibrinolytic to someone whose clot-dissolving system is already shut down may not help and could theoretically increase the risk of unwanted clotting. Viscoelastic blood tests, discussed below, are increasingly used to sort patients into these categories before choosing treatment.
Desmopressin (DDAVP) is another systemic hemostatic agent, but it works through a completely different pathway. It acts on the endothelium, the inner lining of blood vessels, stimulating the release of von Willebrand factor and tissue plasminogen activator from storage compartments called Weibel-Palade bodies.9PubMed. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP) The von Willebrand factor helps platelets stick to damaged vessel walls, making desmopressin particularly useful in patients with von Willebrand disease or certain platelet disorders.
Clotting factor concentrates provide yet another systemic approach. Prothrombin complex concentrate (PCC) supplies a mix of clotting factors II, VII, IX, and X, essentially restoring the raw materials the coagulation cascade needs. In a porcine trauma model where the animals had been deliberately diluted of their clotting factors, PCC shortened time to hemostasis after spleen injury to a median of 35 minutes, compared with 94 minutes for recombinant factor VIIa, and generated substantially more thrombin.10PubMed. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model These concentrates are also the frontline treatment for reversing the anticoagulant warfarin in emergency bleeding.
Tranexamic Acid in Obstetric Bleeding
Postpartum hemorrhage is one of the leading causes of maternal death worldwide, and tranexamic acid has become a key part of its management. The evidence here is unusually clear on timing: tranexamic acid reduced bleeding-related mortality when given within three hours of childbirth, but evidence suggests there is no benefit when the drug is given more than three hours after bleeding onset. The WHO now recommends one gram of intravenous tranexamic acid as soon as possible after postpartum hemorrhage begins, with a second dose if bleeding continues or restarts.11PubMed Central. Tranexamic acid for post-partum haemorrhage: What, who and when
The story gets more nuanced when tranexamic acid is given preventively rather than as treatment. A large trial tested it as a prophylactic measure during cesarean delivery and found no statistically significant reduction in the primary outcome of estimated blood loss over 1,000 mL or need for transfusion. There was, however, a modest reduction in the need for interventions to manage bleeding complications.12PubMed Central. Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery A multinational systematic review found that prophylactic tranexamic acid at cesarean delivery reduced intraoperative bleeding and the likelihood of severe hemorrhage, but for vaginal deliveries, no substantial impact on the overall incidence of postpartum hemorrhage was seen in large studies. Thromboembolic events remained rare and comparable to placebo across all settings.13PubMed Central. Tranexamic Acid in Postpartum Hemorrhage Management: A Multinational Systematic Review of Efficacy and Safety in Both Vaginal and Cesarean Births The takeaway for obstetric care is that tranexamic acid is most clearly beneficial as early treatment once hemorrhage has started, while its preventive use remains a judgment call depending on the clinical scenario.
Reversing Blood Thinners in an Emergency
Millions of people take anticoagulant medications to prevent strokes and blood clots, but when those patients need emergency surgery or suffer traumatic bleeding, their intentionally impaired clotting becomes a life-threatening liability. A new class of hemostatic medicines exists specifically to neutralize these drugs.
Idarucizumab is an antibody fragment that binds and inactivates dabigatran, a direct thrombin inhibitor. In an ex vivo spiking study using blood samples from trauma patients, adding idarucizumab dropped dabigatran plasma levels from a mean of about 324 ng/mL to just 6 ng/mL, effectively eliminating the drug’s anticoagulant effect. Andexanet alfa works against factor Xa inhibitors like apixaban, rivaroxaban, and edoxaban. It reduced apixaban plasma levels by about 94%, rivaroxaban by about 88%, and edoxaban by about 76%.14PubMed Central. Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro® Clotting Time The practical significance is enormous. Before these reversal agents existed, surgeons operating on patients taking newer blood thinners had few good options for controlling bleeding. Now they can pharmacologically undo the anticoagulation within minutes.
Guiding Hemostatic Therapy with Viscoelastic Testing
One of the most important recent advances is not a hemostatic medicine itself but a diagnostic tool that determines which medicine to use. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) are point-of-care blood tests that measure the entire process of clot formation, strengthening, and breakdown in real time using a small whole-blood sample. Unlike traditional lab tests that measure isolated pieces of the clotting cascade, these viscoelastic tests provide a complete picture within minutes.
In trauma resuscitation, viscoelastic tests direct early transfusion of plasma when clinical judgment alone has not triggered a massive transfusion protocol. They detect low fibrinogen levels that call for cryoprecipitate, identify weak clots that need platelets, and pick up excessive clot breakdown, a finding tied to significantly increased mortality that conventional clotting tests cannot reliably detect.15PubMed Central. The Role of TEG and ROTEM in Damage Control Resuscitation They can also flag the presence of direct oral anticoagulants in a patient’s system, helping the team decide whether a reversal agent is needed. While debate continues about whether viscoelastic-guided protocols reduce overall mortality, they consistently speed up diagnosis and reduce unnecessary blood product transfusions.16The Review of Diabetic Studies. The Role Of Viscoelastic Hemostatic Assays (TEG And ROTEM) In Goal-Directed Hemostatic Resuscitation for Trauma-Induced Coagulopathy
Complications and Safety Concerns
Hemostatic agents are not without risk, and some of those risks are not immediately obvious. Topical agents left inside the body after surgery can swell unpredictably. Oxidized regenerated cellulose, for example, has been reported to expand and compress adjacent structures. In orbital surgery, swollen cellulose was mistaken for a postoperative hematoma on imaging and turned out to be causing compressive optic neuropathy by pressing against the optic nerve.17PubMed. Compressive optic neuropathy after use of oxidized regenerated cellulose in orbital surgery Animal studies have suggested that the nerve damage from oxidized cellulose may not even be mechanical; instead, a diffusible chemical mechanism appears to be the main culprit.18PubMed. Oxidized cellulose causes focal neuropathy, possibly by a diffusible chemical mechanism Similarly, in spinal surgery, a widely used cellulose hemostat has been found to swell into a horseshoe-shaped mass compressing the dural sac, mimicking a hematoma and requiring reoperation. The recommendation from that case was that surgeons remove these products after hemostasis is achieved whenever possible.19PubMed. Massive swelling of Surgicel® Fibrillar™ hemostat after spinal surgery
Bovine thrombin, once a ubiquitous component of surgical hemostatic products, introduces immunological concerns. These preparations are highly immunogenic: one prospective study of 309 patients found that about 19% developed antibodies against bovine thrombin and 30% against bovine factor Va after surgical exposure.20Journal of Investigative Surgery. Antigenic Responses to Bovine Thrombin Exposure During Surgery: A Prospective Study of 309 Patients In that particular study, none of the antibody-positive patients showed evidence of clinical bleeding complications. But other reports have documented an array of adverse events following bovine thrombin exposure, including antibodies that cross-react with human clotting factors and lead to syndromes ranging from severe postoperative bleeding to graft thrombosis.21PubMed. The clinical use and immunologic impact of thrombin in surgery A separate study concluded that bovine thrombin appears to be associated with increased risk of adverse outcomes during subsequent surgeries and that reexposure should likely be avoided.22PubMed Central. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin The inconsistency across studies is itself informative: immune responses to bovine thrombin are common, but whether they cause clinically meaningful harm probably depends on factors like dose, number of exposures, and the individual patient’s immune response. Recombinant human thrombin products were developed in part to sidestep this issue.
Systemic hemostatic agents carry a different category of risk: unwanted clotting. Any drug that promotes coagulation has the theoretical potential to cause thromboembolism. A case report described a patient with a rare platelet disorder who developed bilateral pulmonary embolism two months after surgery, following a perioperative regimen that included recombinant factor VIIa, platelet transfusions, and tranexamic acid.23PubMed Central. Pulmonary thromboembolism in Glanzmann Thrombasthenia: a case report and systematic literature review While such events are uncommon, they underscore the fundamental tension in hemostatic medicine: every intervention that tips the balance toward clotting also increases the risk of tipping too far.
Patients with Liver Disease
The liver manufactures most clotting factors, so patients with cirrhosis present a unique hemostatic challenge. Their clotting tests often look abnormal, but the reality is more complex: cirrhosis impairs both pro-coagulant and anti-coagulant pathways simultaneously, creating a fragile equilibrium that can tip toward either bleeding or thrombosis. The prevalence of cirrhosis among patients undergoing elective surgery sits at roughly 0.8%, which translates to about 25 million cirrhotic patients undergoing surgery each year worldwide. Cirrhosis independently raises the risk of postoperative complications by about 47% and more than doubles the risk of dying in the hospital after elective surgery.24PubMed. Perioperative hemostatic management in the cirrhotic patient: a position paper on behalf of the Liver Intensive Care Group of Europe (LICAGE) For these patients, conventional clotting tests are poor predictors of actual bleeding risk, and the viscoelastic tests described above are increasingly used to guide more targeted hemostatic management rather than blanketing every cirrhotic patient with plasma and platelets.
Experimental Hemostats on the Horizon
The next generation of hemostatic materials is being built at the nanoscale. Self-assembling peptide hydrogels are synthetic materials whose molecules spontaneously arrange themselves into nanofibrous meshworks when they contact blood or wound tissue. Early lab work shows these gels can physically cover and adhere to bleeding points, forming a barrier against blood loss from arterial and venous injuries as well as solid organ damage.25ACS Omega. Experimental Study on Rapid Hemostasis Using Peptide Hydrogels One creative application loaded a peptide hydrogel with batroxobin, an enzyme derived from snake venom that converts fibrinogen into fibrin directly, bypassing the normal coagulation cascade entirely. In a rat liver injury model, this snake-venom-loaded hydrogel stopped bleeding within 20 seconds, and it worked even in animals treated with heparin, a potent anticoagulant.26PubMed Central. Nanofibrous Snake Venom Hemostat
Another approach uses a “nano-band-aid” constructed from two functionalized peptides that coassemble into nanofibers and then weave into a meshlike network in the presence of calcium ions. A third stage of assembly, triggered by the body’s own clotting factor XIIIa, compacts the mesh into a dense physical barrier.27PubMed. A Bionic Nano-Band-Aid Constructed by the Three-Stage Self-Assembly of Peptides for Rapid Liver Hemostasis Separately, researchers are developing nanoparticle-based systemic hemostats that circulate in the bloodstream and concentrate at bleeding sites. One prototype uses a prodrug strategy: the nanoparticle initially promotes clotting at the injury, then its payload is metabolized into an antiplatelet compound over several hours, reducing the risk of thrombosis after the acute bleeding is controlled.28PubMed. An anticoagulant/procoagulant self-converting and bleeding site-targeting systemic nanotherapy for rapidly controlling noncompressible bleeding without risk of thrombosis That self-converting behavior, procoagulant first and then anticoagulant, would address the central safety dilemma of systemic hemostats if it translates successfully from animal models to human use. All of these technologies remain in early-stage testing, but they hint at a future where hemostatic medicines are more targeted, more versatile, and less likely to cause the very complications they are deployed to prevent.